Neoadjuvant Therapy for Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 17, 2010

Primary Completion Date

April 13, 2015

Study Completion Date

April 13, 2015

Conditions
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Carboplatin

Carboplatin will be administered at a concentration-time curve (AUC) of 5-6 (at the discretion of the physician) day 1 every 3 weeks in combination with Paclitaxel and Bevacizumab.

DRUG

Paclitaxel

Paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks in combination with Carboplatin and Bevacizumab.

DRUG

Bevacizumab

Bevacizumab 15 mg/kg day 1 every 3 weeks in combination with Paclitaxel and Carboplatin.

Trial Locations (3)

10032

Columbia University Medical Center, New York

19111

Fox Chase Cancer Center, Philadelphia

22908

University of Virginia, Charlottesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Jason D. Wright

OTHER